<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7707449</journal-id>
<journal-id journal-id-type="pubmed-jr-id">656</journal-id>
<journal-id journal-id-type="nlm-ta">Ann Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann. Neurol.</journal-id>
<journal-title-group>
<journal-title>Annals of neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0364-5134</issn>
<issn pub-type="epub">1531-8249</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30937933</article-id>
<article-id pub-id-type="pmc">6800210</article-id>
<article-id pub-id-type="doi">10.1002/ana.25477</article-id>
<article-id pub-id-type="manuscript">NIHMS1054668</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recurrent <italic>SLC1A2</italic> variants cause epilepsy via a dominant negative mechanism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Stergachis</surname>
<given-names>Andrew B.</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pujol-Giménez</surname>
<given-names>Jonai</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gyimesi</surname>
<given-names>Gergely</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fuster</surname>
<given-names>Daniel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Albano</surname>
<given-names>Giusppe</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Troxler</surname>
<given-names>Marina</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Picker</surname>
<given-names>Jonathan</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>Paul A.</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bergin</surname>
<given-names>Ann</given-names>
</name>
<degrees>MB, ScM, MRCP</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peters</surname>
<given-names>Jurriaan</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Achkar</surname>
<given-names>Christelle Moufawad El</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harini</surname>
<given-names>Chellamani</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manzi</surname>
<given-names>Shannon</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rotenberg</surname>
<given-names>Alexander</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hediger</surname>
<given-names>Matthias A.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodan</surname>
<given-names>Lance H.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA</aff>
<aff id="A2"><label>2</label>Department of Nephrology and Hypertension, University Hospital Bern, Inselspital, Bern, Switzerland.</aff>
<aff id="A3"><label>3</label>Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.</aff>
<aff id="A4"><label>4</label>Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA</aff>
<aff id="A5"><label>5</label>Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA</aff>
<aff id="A6"><label>6</label>Department of Pharmacy, Boston Children’s Hospital, Harvard Medical School, Boston, MA</aff>
<aff id="A7"><label>7</label>These authors contributed equally to this work</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">Author Contributions</p>
<p id="P2">A.B.S, L.H.R., J.P., P.A.R., A.B., J.P., C.M.E.A, C.H., S.M., and A.R. contributed to the ceftriaxone trial study concept and design. A.B.S, J.P-G., M.A.H. and L.H.R. contrinuted to the <italic>in vitro</italic> study concept and design. A.B.S, L.H.R., and A.R. contrinuted to the ceftriaxone trial data acquisition and analysis. J.P-G., A.B.S, G.G., D.F., G.A., M.T., L.H.R. and M.A.H. contrinuted to the <italic>in vitro</italic> data acquisition and analysis. A.B.S, J.P-G., M.A.H. and L.H.R. drafted the manuscript and figures.</p>
</fn>
<corresp id="CR1"><label>*</label>Correspondence: <email>lance.rodan@childrens.harvard.edu</email> (L.H.R.), <email>matthias.hediger@ibmm.unibe.ch</email> (M.A.H.)</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P17">Conflicts of Interest</p>
<p id="P18">No significant conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>85</volume>
<issue>6</issue>
<fpage>921</fpage>
<lpage>926</lpage>
<!--elocation-id from pubmed: 10.1002/ana.25477-->
<abstract id="ABS1">
<p id="P3"><italic>SLC1A2</italic> is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent <italic>de novo SLC1A2</italic> missense variants cause a severe, early-onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all three variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old <italic>SLC1A2</italic>-related epilepsy patient with the SLC1A2 modulating agent ceftriaxone did not result in a significant change in daily spasm count.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>